The DOI matches its Crossref record; 236 of the 236 references it cites were found in a registry or an index.
Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review
Open accessAbstract
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and has an exceedingly low median overall survival of only 15 months. Current standard-of-care for GBM consists of gross total surgical resection followed by radiation with concurrent and adjuvant chemotherapy. Temozolomide (TMZ) is the first-choice chemotherapeutic agent in GBM; however, the development of resistance to TMZ often becomes the limiting factor in effective treatment. While O6-methylguanine-DNA methyltransferase repair activity and uniquely resistant populations of glioma stem cells are the most well-known contributors to TMZ resistance, many other molecular mechanisms have come to light in recent years. Key emerging mechanisms include the involvement of other DNA repair systems, aberrant signaling pathways, autophagy, epigenetic modifications, microRNAs, and extracellular vesicle production. This review aims to provide a comprehensive overview of the clinically relevant molecular mechanisms and their extensive interconnections to better inform efforts to combat TMZ resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–236 of 236
Chen, K., Chen, P., Ho, K., Shih, C.-M., Chou, C., Cheng, C., & Lee, C.-C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225913 · Cited by 44
Contribution of the Wnt Pathway to Defining Biology of Glioblastoma
Tompa, M., Kálovits, F., Nagy, Á., & Kálmán, B. (2018) · NeuroMolecular Medicine · doi:10.1007/s12017-018-8514-x · Cited by 43
Champeaux-Depond, C., & Weller, J. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03410-1 · Cited by 43
Harder, B. G., Peng, S., Sereduk, C., Sodoma, A. M., Kitange, G. J., Loftus, J. C., Sarkaria, J. N., & Tran, N. L. (2019) · Molecular Medicine · doi:10.1186/s10020-019-0116-z · Cited by 42
Santos‐Barriopedro, I., Li, Y., Bahl, S., & Seto, E. (2019) · Genes & Cancer · doi:10.18632/genesandcancer.197 · Cited by 41
Histone Deacetylase Inhibitors in Tumor Immunotherapy
Zhao, L., & Zhang, J. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170801102124 · Cited by 40
Kim, G. W., Lee, D. H., Yeon, S.-K., Jeon, Y. H., Yoo, J. H., Lee, S. W., & Kwon, S. H. (2019) · Anticancer Research · doi:10.21873/anticanres.13888 · Cited by 40
Shi, L., Wan, Y., Sun, G., Zhang, S., Wang, Z., & Zeng, Y. (2013) · BioDrugs · doi:10.1007/s40259-013-0053-2 · Cited by 39
Zhang, S., Han, L., WEI, J., Shi, Z., Pu, P., Zhang, J., Yuan, X., & Kang, C. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2841 · Cited by 39
Carter, T. C., Medina‐Flores, R., & Lawler, B. (2018) · BioMed Research International · doi:10.1155/2018/6204676 · Cited by 39
Lee, D., Sun, S., Zhang, X. Q., Zhang, P. D., Ho, A. S.-W., Kiang, K. M. Y., Fung, C. F., Lui, W., & Leung, G. (2015) · Journal of Cancer · doi:10.7150/jca.10765 · Cited by 37
Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma
Velpula, K. K., Guda, M. R., Sahu, K., Tuszyński, J. A., Asuthkar, S., Bach, S. E., Lathia, J. D., & Tsung, A. J. (2017) · Oncotarget · doi:10.18632/oncotarget.16767 · Cited by 37
The Role of miRNA for the Treatment of MGMT Unmethylated Glioblastoma Multiforme
Kirstein, A., Schmid, T. E., & Combs, S. E. (2020) · Cancers · doi:10.3390/cancers12051099 · Cited by 36
Josset, E., Burckel, H., Noël, G., et al. (2013) · PubMed · Cited by 35
Lu, J., Zhang, F., Zhao, D., Hong, L., Min, J., Zhang, L., Li, F., Yan, Y., Li, H., Ma, Y., et al. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9518-4 · Cited by 35
Yang, M., Loh, J., Li, Y., Huang, W., Chou, C., Cheng, J., Wang, Y., Lieu, A., Howng, S., Hong, Y., et al. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2838 · Cited by 33
Expression of DNA mismatch repair proteins MLH1, MSH2, and MSH6 in recurrent glioblastoma
Stark, A. M., Doukas, A., Hugo, H. ‐., Hedderich, J., Hattermann, K., Mehdorn, H. M., & Held‐Feindt, J. (2014) · Neurological Research · doi:10.1179/1743132814y.0000000409 · Cited by 32
Guberina, N., Pöttgen, C., Kebir, S., Lazaridis, L., Scharmberg, C., Lübcke, W., Niessen, M., Guberina, M., Scheffler, B., Jendrossek, V., et al. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01521-7 · Cited by 32
MicroRNA and Brain Tumors: A Cause and a Cure?
Mathupala, S. P., Mittal, S., Guthikonda, M., & Sloan, A. E. (2007) · DNA and Cell Biology · doi:10.1089/dna.2006.0560 · Cited by 31
Self-citationLohitesh, K., Saini, H., Srivastava, A., Mukherjee, S., Roy, A., & Chowdhury, R. (2018) · Oncology Reports · doi:10.3892/or.2018.6373 · Cited by 31
Lee, H., Lin, C.-H., Lin, H.-Y., Kuei, C., Zheng, J.-Q., Wang, Y., Lu, L., Lee, F., Hu, C., Wu, D., et al. (2019) · Cancers · doi:10.3390/cancers12010098 · Cited by 31
Cui, P., Wei, F., Hou, J., Su, Y., Wang, J., & Wang, S. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109598 · Cited by 30
Shi, J., Zhang, L., Shen, A., Zhang, J., Wang, Y., Zhao, Y., Zou, L., Ke, Q., He, F., Wang, P., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-0045-8 · Cited by 28
Nadaradjane, A., Briand, J., Bougras-Cartron, G., Disdero, V., Vallette, F. M., Frenel, J., & Cartron, P. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.09.007 · Cited by 27
Yelton, C. J., & Ray, S. K. (2018) · Neuroimmunology and Neuroinflammation · doi:10.20517/2347-8659.2018.58 · Cited by 25
Song, Z., Pan, Y., Ling, G., Wang, S., Huang, M., Jiang, X., & Ke, Y. (2017) · Europe PMC (PubMed Central) · Cited by 25
CHEN, C.-M., Syu, J.-P., Way, T., Huang, L., Kuo, S., Lin, C., & Lin, C. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2332 · Cited by 24
MicroRNAs in Cancer Translational Research
Cho, W. (2011) · Springer eBooks · doi:10.1007/978-94-007-0298-1 · Cited by 23
Growth-inhibitory and chemosensitizing effects of microRNA-31 in human glioblastoma multiforme cells
Zhou, R., Xiong-ying, X., LIU, B.-X., DAI, W.-Z., Cai, M., BAI, C.-F., ZHANG, X.-F., Wang, L., Lin, L., JIA, S.-Z., et al. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2312 · Cited by 23
Xu, K., Zhang, Z., Pei, H., Wang, H., Li, L., & Xia, Q. (2020) · Oncology Reports · doi:10.3892/or.2020.7842 · Cited by 19
The role of extracellular vesicles in acquisition of resistance to therapy in glioblastomas
Yekula, A., Taylor, A., Beecroft, A., Kang, K. M., Small, J. L., Muralidharan, K., Rosh, Z. S., Carter, B. S., & Balaj, L. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.61 · Cited by 19
Snail expression contributes to temozolomide resistance in glioblastoma.
Liang, H., Chen, G., Li, J., & Yang, F. (2019) · PubMed · Cited by 16
PDK1: A New Therapeutic Target for Glioblastoma?
Velpula, K. K., & Tsung, A. J. (2014) · CNS Oncology · doi:10.2217/cns.14.13 · Cited by 14
Exploitation of adaptive evolution in glioma treatment
Cordner, R., Black, K. L., & Wheeler, C. J. (2013) · CNS Oncology · doi:10.2217/cns.12.46 · Cited by 12
RNAi-based Approaches to the Treatment of Brain Tumors
Mathupala, S. P., Mittal, S., Guthikonda, M., & Sloan, A. E. (2010) · Springer eBooks · doi:10.1007/978-94-007-0298-1_22 · Cited by 2
Self-citationThe Therapeutic Role of MicroRNAs in Human Gliomas
Sarkar, S. H., Ahmad, A., & Mittal, S. (2014) · Springer eBooks · doi:10.1007/978-3-319-05134-5_1 · Cited by 2
Self-citation
Cited by
Tomar, M. S., Kumar, A., Srivastava, C., & Shrivastava, A. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188616 · Cited by 325
Glioblastoma at the crossroads: current understanding and future therapeutic horizons
Singh, S., Dey, D., Barik, D., Mohapatra, I., Kim, S., Sharma, M., Prasad, S., Wang, P., Singh, A., & Singh, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02299-4 · Cited by 287
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Metadata
- Authors
- Singh, N., Miner, A., Hennis, L., & Mittal, S.
- Venue
- Cancer Drug Resistance
- Publisher
- OAE Publishing Inc.
- Published
- 2020
- Volume
- 4
- Pages
- 17-43
- ISSN
- 2578-532X (ISSN-L)
- OpenAlex
- W3109004754
- Cited by
- 398
- References
- 236
- FWCI
- 16.28
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.